Biotech Alert: Searches spiking for these stocks today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2025
0mins
Source: Business Insider
Biotech Stocks Surge in Interest: Several biotech companies, including Vaxcyte and Maravai LifeSciences, are experiencing significant increases in search activity, indicating heightened investor interest. This surge is attributed to their innovative developments and potential market impact.
Recent Developments and Analyst Ratings: Companies like Madrigal Pharmaceuticals and Geron have received various analyst upgrades and downgrades based on recent earnings reports and clinical trial results, reflecting the volatile nature of biotech investments influenced by upcoming FDA approvals and study outcomes.
Analyst Views on ABUS
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





